

VPA10815/065/001

Syncroprost, 0.250 mg/ml solution for injection for cattle, horses, pigs and goats

Variation	Summary	Date
Vet - A1 a)	VNRA - Vet - A1 a) - - A1 a) Administrative changes - Change in the name or address of - the marketing authorisation holder	25/08/25
Vet - G.I.2 b)	VRA-S - Vet - G.I.2 b) - b) Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product - G.I.2 b) Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid medicinal product following assessment of the same change for the reference product - Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product	01/07/25
Vet - F.II.f.1 z)	VRA-R - Vet - F.II.f.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.f.1 z) Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	02/04/25
Vet - F.II.b.4 z)	VRA-R - Vet - F.II.b.4 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.4 z) Quality Changes - Finished Product -Manufacture - Change in the batch size (including batch size ranges) of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	02/04/25
Vet - B27 b)	VNRA - Vet - B27 b) - b) Addition of a new in-process test and limits - B27 b) Changes to the quality part of the dossier: Change to in-process tests or limits applied during the manufacture of the finished product: — addition of a new in-process test and limits	25/03/25
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	23/04/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	23/04/24
Vet - G.I.18	VRA-E - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD	02/02/24

	templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	
Vet - F.II.e.5 b)	VRA-E - Vet - F.II.e.5 b) - b) Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products. - F.II.e.5 b) Quality Changes - Container closure system -Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products.	02/02/24
Vet - F.II.e.5 b)	VRA-E - Vet - F.II.e.5 b) - b) Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products. - F.II.e.5 b) Quality Changes - Container closure system -Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products.	02/02/24